Trimazosin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Trimazosin
Accession Number
DB09206
Type
Small Molecule
Groups
Experimental
Description

Trimazosin is a sympatholytic alpha blocker.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Trimazosin hydrochloride827T79ILE753746-46-6WXMXALSEIGHTOR-UHFFFAOYSA-N
Categories
UNII
31L760807H
CAS number
35795-16-5
Weight
Average: 435.481
Monoisotopic: 435.211783674
Chemical Formula
C20H29N5O6
InChI Key
YNZXWQJZEDLQEG-UHFFFAOYSA-N
InChI
InChI=1S/C20H29N5O6/c1-20(2,27)11-31-19(26)25-8-6-24(7-9-25)18-22-14-12(17(21)23-18)10-13(28-3)15(29-4)16(14)30-5/h10,27H,6-9,11H2,1-5H3,(H2,21,22,23)
IUPAC Name
2-hydroxy-2-methylpropyl 4-(4-amino-6,7,8-trimethoxyquinazolin-2-yl)piperazine-1-carboxylate
SMILES
COC1=CC2=C(N=C(N=C2N)N2CCN(CC2)C(=O)OCC(C)(C)O)C(OC)=C1OC

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid may increase the hypotensive activities of Trimazosin.
1-benzylimidazoleThe risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Trimazosin.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of hypertension can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Trimazosin.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of hypertension can be increased when Trimazosin is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3,4-MethylenedioxyamphetamineThe risk or severity of hypertension can be increased when 3,4-Methylenedioxyamphetamine is combined with Trimazosin.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of hypertension can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Trimazosin.
4-MethoxyamphetamineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Trimazosin.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of hypertension can be increased when Trimazosin is combined with 5-methoxy-N,N-dimethyltryptamine.
AbediterolThe therapeutic efficacy of Abediterol can be decreased when used in combination with Trimazosin.
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Trimazosin.
Food Interactions
Not Available

References

General References
  1. van Kalken CK, van der Meulen J, Oe PL, Vriesendorp R, Donker AJ: Pharmacokinetics of trimazosin and its effects on blood pressure, renal function and proteinuria during short-term therapy of patients with impaired renal function and hypertension. Eur J Clin Pharmacol. 1986;31(1):63-8. [PubMed:3780829]
External Links
PubChem Compound
37264
PubChem Substance
310265114
ChemSpider
34203
ChEBI
135710
ChEMBL
CHEMBL513301
Wikipedia
Trimazosin
ATC Codes
C02CA03 — Trimazosin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US3669968No1972-06-131992-06-13Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.56 mg/mLALOGPS
logP1.35ALOGPS
logP1.2ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)14.59ChemAxon
pKa (Strongest Basic)5.99ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area132.5 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity114.87 m3·mol-1ChemAxon
Polarizability46.3 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
N-arylpiperazines
Alternative Parents
Quinazolinamines / Piperazine carboxylic acids / Anisoles / Dialkylarylamines / Alkyl aryl ethers / Aminopyrimidines and derivatives / Imidolactams / Tertiary alcohols / Heteroaromatic compounds / Carbamate esters
show 7 more
Substituents
N-arylpiperazine / Quinazolinamine / Diazanaphthalene / Quinazoline / Piperazine-1-carboxylic acid / Anisole / Dialkylarylamine / Alkyl aryl ether / Aminopyrimidine / Pyrimidine
show 20 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 19, 2015 14:32 / Updated on November 02, 2018 08:56